-+ 0.00%
-+ 0.00%
-+ 0.00%

Zura Bio releases investor presentation on tibulizumab dual IL-17 and BAFF blockade in immune disorders

PUBT·07/01/2026 20:17:23
Listen to the news
Zura Bio releases investor presentation on tibulizumab dual IL-17 and BAFF blockade in immune disorders
  • Zura Bio highlighted tibulizumab, a bispecific antibody designed to inhibit IL-17 and BAFF pathways in complex immune disorders.
  • Phase 2 hidradenitis suppurativa trial enrollment completed; 247 participants randomized; topline data expected in Q4 2026.
  • Phase 2 systemic sclerosis trial expected to complete enrollment in early July 2026; enrollment exceeded 80 participants; topline data expected in 1H 2027.
  • Company plans to start a Phase 2 trial in a third immune-mediated indication by year-end 2026.
  • Cash and cash equivalents of about $225.6 million as of March 31, 2026; February 2026 offering expected to fund operations through at least end-2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.